Universite de Lausanne
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
1
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Kinase Mutants and Uses Thereof (US 11,738,049) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Method and a system for matching subscriptions with publications (US 10,506,368) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,975,370 | Inhibitor proteins of a protease and use thereof In force · High confidence | In force | High confidence | |
| US 10,815,310 | Multispecific Antigen Binding Fragments and Multispecific Antibodies Derived Therefrom Comprising Mutant CH1 and Cl-Kappa Domains In force · Medium confidence | In force | Medium confidence | |
| US 12,378,325 | Multispecific Antigens Binding Fragments and Multspecific Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 11,193,171 | Diagnostic, Prognostic and Therapeutic Uses of Long Noncoding RNAs for Heart Disease and Regenerative Medicine In force · High confidence | In force | High confidence | |
| US 12,649,948 | Diagnostic, Prognostic And Therapeutic Uses Of Long Noncoding RNAs For Heart Disease And Regenerative Medicine In force · High confidence | In force | High confidence | |
| US 10,506,368 | Method and a system for matching subscriptions with publications In force · From the USPTO record | In force | From the USPTO record | |
| US 12,478,626 | Kinase Mutants and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,491,205 | Methods And Compositions For Controlling Cardiac Fibrosis And Remodeling In force · High confidence | In force | High confidence | |
| US 11,738,049 | Kinase Mutants and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,167,731 | Fungicides to Prevent and Control Fungal Pathogens In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 2 patents in force now held by others · 15 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 4 abandoned · 16 no status recorded